sunitinib krka 50 mg kapseli, kova
krka, d.d., novo mesto - sunitinib malate - kapseli, kova - 50 mg - sunitinibi
sunitinib krka 25 mg kapseli, kova
krka, d.d., novo mesto - sunitinib malate - kapseli, kova - 25 mg - sunitinibi
sunitinib krka 12.5 mg kapseli, kova
krka, d.d., novo mesto - sunitinib malate - kapseli, kova - 12.5 mg - sunitinibi
sunitinib avansor 50 mg kapseli, kova
avansor pharma oy - sunitinib malate - kapseli, kova - 50 mg - sunitinibi
sunitinib avansor 25 mg kapseli, kova
avansor pharma oy - sunitinib malate - kapseli, kova - 25 mg - sunitinibi
sunitinib avansor 12.5 mg kapseli, kova
avansor pharma oy - sunitinib malate - kapseli, kova - 12.5 mg - sunitinibi
jakavi
novartis europharm limited - ruxolitinibi (fosfaatteina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiset aineet - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polysytemia vera (pv)jakavi on tarkoitettu aikuisille potilaille, joilla on polysytemia vera, jotka ovat resistenttejä tai intolerantteja ja hydroksiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
opzelura
incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muut dermatologiset valmisteet - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
sutent
pfizer limited - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
jakavi 5 mg resepti
tabletti - l01xe18 ruksolitinibi [näytä works saman ryhmän lääkevalmisteet] - resepti - 5 mg